Pfizer Inc. (NYSE:PFE) Shares Purchased by Capital Investment Advisory Services LLC

Capital Investment Advisory Services LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 76.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 200,570 shares of the biopharmaceutical company's stock after buying an additional 86,726 shares during the quarter. Capital Investment Advisory Services LLC's holdings in Pfizer were worth $5,321,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the fourth quarter valued at $26,000. Gladius Capital Management LP boosted its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP acquired a new stake in Pfizer in the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management lifted its position in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 771 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. Guggenheim cut their price target on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Price Performance

Shares of PFE stock traded up $0.27 during midday trading on Thursday, reaching $26.89. 32,270,209 shares of the company traded hands, compared to its average volume of 35,838,855. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market cap of $152.41 billion, a PE ratio of 36.34, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm's 50 day simple moving average is $26.22 and its two-hundred day simple moving average is $27.90. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.40%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.